

Human/Rat BDNF sandwich ELISA kit datasheet

For the quantitative detection of human/rat BDNF in serum, plasma and cell culture supernatants.

general information

Catalogue Number	KE00096
Product Name	Human/Rat BDNF ELISA Kit
Species cross-reactivity	Human/Rat BDNF
Range (calibration Range)	12.5 - 800 pg/mL
Tested applications	Quantification ELISA

database links

Entrez Gene	627 (Human) / 24225 (Rat)
SwissProt	P23560 (Human) / P23363 (Rat)

kit components & storage


Microplate - antibody coated 96-well Microplate (8 well × 12 strips)	1 plate	Store at 2-8°C for six months
Standard - 1600 pg/bottle; lyophilized*	2 bottles	Store at 2-8°C for six months
Detection Antibody (100X), biotinylated - 120 µL/vial	1 vial	Store at 2-8°C for six months
Streptavidin-HRP antibody (100X) - 120 µL/vial	1 vial	Store at 2-8°C for six months
Sample Diluent PT 1-ec - 30 mL/bottle	1 bottle	Store at 2-8°C for six months
Detection Diluent - 30 mL/bottle	1 bottle	Store at 2-8°C for six months
Wash Buffer Concentrate (20X) - 30 mL/bottle	1 bottle	Store at 2-8°C for six months
Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle	1 bottle	Store at 2-8°C for six months
Stop Solution - 12 mL/bottle	1 bottle	Store at 2-8°C for six months
Plate Cover Seals	3 pieces	

NB: Do not use the kit after the expiration date.

Sample Diluent PT 1-ec is for standard and samples.

Detection Diluent is for Detection antibody and Streptavidin-HRP antibody.

*Add 2 mL Sample Diluent PT 1-ec in standard. This reconstitution gives a stock solution of 800 pg/mL.



Add # µL of Standard diluted in the previous step	—	500 µL	500 µL	500 µL	500 µL	500 µL	500 µL
# µL of Sample Diluent PT 1-ec	2000 µL	500 µL	500 µL	500 µL	500 µL	500 µL	500 µL
	"sd7"	"sd6"	"sd5"	"sd4"	"sd3"	"sd2"	"sd1"

product description

KE00096 is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (Sandwich ELISA). The BDNF ELISA kit is to be used to detect and quantify protein levels of endogenous BDNF. The assay recognizes human BDNF. An antibody specific for BDNF has been pre-coated onto the microwells. The BDNF protein in samples is captured by the coated antibody after incubation. Following extensive washing, another antibody of biotinylated specific for human BDNF is added to detect the captured human BDNF protein. For signal development, Streptavidin-HRP is added, followed by Tetramethyl-benzidine (TMB) reagent. Solution containing sulfuric acid is used to stop color development and the color intensity which is proportional to the quantity of bound protein is measurable at 450nm with the correction wavelength set at 630 nm.

background

The brain-derived neurotrophic factor (BDNF), as a member of the neurotrophin family of growth factors, is broadly expressed in the central nervous system. BDNF is involved in cerebral morphogenesis, synaptic plasticity and learning, mental health, degenerative central nervous system (CNS) diseases, and energy metabolism. BDNF has recently been identified as one of the four major pharmaceutical targets in neuropsychiatric diseases, including depression and bipolar disorder. In addition, BDNF is increasingly considered as a potential therapeutic agent for neurodevelopmental disorders such as Rett syndrome.

sample preparation

The serum or plasma samples may require proper dilution to fall within the range of the assay. A range of dilutions like 1:50 is suggested according to the individual samples.

safety notes


This product is sold for lab research and development use ONLY and not for use in humans or animals. Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.

assay procedure summary

Step	Reagent	Volume	Incubation	Wash	Notes
1	Standard and Samples	100 µL	120 min	4 times	Cover Wells incubate at 37°C
2	Diluent Antibody Solution	100 µL	60 min	4 times	Cover Wells incubate at 37°C
3	Diluent HRP Solution	100 µL	40 min	4 times	Cover Wells incubate at 37°C
4	TMB Substrate	100 µL	15-20 min	Do not wash	Incubate in the dark at 37°C
5	Stop Solution	100 µL	0 min	Do not wash	-
6	Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes.				

typical data

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(pg/mL)	O.D	Average	Corrected
0	0.038	0.035	—
	0.031		
12.5	0.116	0.111	0.077
	0.106		
25	0.164	0.183	0.149
	0.202		
50	0.306	0.323	0.288
	0.339		
100	0.622	0.631	0.596
	0.639		
200	1.067	1.038	1.004
	1.009		
400	1.615	1.737	1.703
	1.859		
800	2.471	2.570	2.536
	2.669		

precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

Sample	Intra-assay Precision			Inter-assay Precision		
	1	2	3	1	2	3
n	20	20	20	24	24	24
Mean (pg/mL)	35.8	116.5	513.9	32.2	108.6	517.3
SD	2.3	9.2	36.9	2.6	8.2	40.8
CV%	6.3	7.9	7.2	8.1	7.6	7.9

recovery

The recovery of BDNF spiked to three different levels in four samples throughout the range of the assay in various matrices was evaluated.

Sample Type		Average% of Expected	Range (%)
Human plasma	1:50	91	74-110
	1:100	93	78-117
Cell culture supernatants	1:4	86	73-100
	1:8	94	75-113

sample value

Serum samples from healthy volunteers (human) and normal rat were evaluated for BDNF in this assay. No medical histories were available for the donors used in this study.

Sample Type	Mean of Detectable (pg/mL)	Range (pg/mL)
Human serum (n=32)	11,694	3,146-20,916
Rat serum (n=8)	117	89-177

sensitivity

The minimum detectable dose of human BDNF is 0.1 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

linearity

To assess the linearity of the assay, three samples were spiked with high concentrations of BDNF in various matrices and diluted with the appropriate Sample Diluent to produce samples with values within the dynamic range of the assay. (The plasma samples were initially diluted 1:50)

		Human plasma	Cell culture supernatants
1:2	Average% of Expected	82	78
	Range (%)	74-96	73-86
1:4	Average% of Expected	88	88
	Range (%)	75-109	79-94
1:8	Average% of Expected	97	91
	Range (%)	93-100	82-100
1:16	Average% of Expected	99	79
	Range (%)	76-111	70-87

references

1. Cohen-Cory S. et al. (2010) Dev Neurobiol. 70:271-88.
2. Autry A. et al. (2012) J. Neurosci. 32:14074-14079.
3. Yamada K. et al. (2003) J Pharmacol Sci. 91:267-70.
4. Vaghi V. et al. (2014) J Biol Chem. 289:27702-13.